The estimated Net Worth of Todd Christopher Longsworth is at least $14.9 Million dollars as of 8 March 2022. Mr Longsworth owns over 2,339 units of NovoCure Ltd stock worth over $1,076,220 and over the last 8 years he sold NVCR stock worth over $12,661,533. In addition, he makes $1,154,239 as Gen. Counsel at NovoCure Ltd.
Mr has made over 18 trades of the NovoCure Ltd stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 2,339 units of NVCR stock worth $163,964 on 8 March 2022.
The largest trade he's ever made was exercising 158,440 units of NovoCure Ltd stock on 3 September 2019 worth over $1,527,362. On average, Mr trades about 12,522 units every 48 days since 2017. As of 8 March 2022 he still owns at least 62,462 units of NovoCure Ltd stock.
You can see the complete history of Mr Longsworth stock trades at the bottom of the page.
Todd C. Longsworth is the Gen. Counsel at NovoCure Ltd.
As the Gen. Counsel of NovoCure Ltd, the total compensation of Mr Longsworth at NovoCure Ltd is $1,154,239. There are 8 executives at NovoCure Ltd getting paid more, with William Doyle having the highest compensation of $8,286,100.
Mr Longsworth is 46, he's been the Gen. Counsel of NovoCure Ltd since . There are 19 older and 5 younger executives at NovoCure Ltd. The oldest executive at NovoCure Ltd is Prof. Yoram Palti, 83, who is the Founder & CTO.
Todd's mailing address filed with the SEC is C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN, PA, 19355.
Over the last 9 years, insiders at NovoCure Ltd have traded over $237,132,855 worth of NovoCure Ltd stock and bought 164,174 units worth $2,198,429 . The most active insiders traders include Asaf Danziger, William Fwfd Ventures Fund ..., and Michael J. Ambrogi. On average, NovoCure Ltd executives and independent directors trade stock every 7 days with the average trade being worth of $853,350. The most recent stock trade was executed by Ashley Cordova on 2 August 2024, trading 688 units of NVCR stock currently worth $13,856.
we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.
NovoCure Ltd executives and other stock owners filed with the SEC include: